Infectious diseases now · 2026
Treatment duration of community-acquired pneumonia due to Legionella pneumophila: where do we stand?
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dinh Aurélien, Saliba Michelle, Maulin Laurence, Welker Yves
Аннотация
INTRODUCTION: While recent guidelines for treatment of community-acquired pneumonia (CAP) recommend short antibiotic duration, evidence regarding Legionella pneumophila pneumonia remains limited.
METHODS: We conducted a narrative review of studies identified via PubMed and Embase, including randomized trials, observational studies and meta-analyses assessing treatment duration and outcomes.
RESULTS: No randomized trials specifically address legionellosis. Data from CAP consistently support short courses (≤5-7 days), even for atypical pathogens. Observational studies suggest a clinical course similar to that applied for typical CAP, with rapidly attained stability and short intravenous treatment durations. Meta-analyses show no differences in clinical cure, relapse, or mortality between short and long regimens, with fewer adverse events occurring in shorter courses.
CONCLUSION: While short-course therapy appears appropriate for legionellosis (3-5 days for non-severe cases, 10-14 days for severe cases and/or immunocompromised patients), prospective studies remain needed.
METHODS: We conducted a narrative review of studies identified via PubMed and Embase, including randomized trials, observational studies and meta-analyses assessing treatment duration and outcomes.
RESULTS: No randomized trials specifically address legionellosis. Data from CAP consistently support short courses (≤5-7 days), even for atypical pathogens. Observational studies suggest a clinical course similar to that applied for typical CAP, with rapidly attained stability and short intravenous treatment durations. Meta-analyses show no differences in clinical cure, relapse, or mortality between short and long regimens, with fewer adverse events occurring in shorter courses.
CONCLUSION: While short-course therapy appears appropriate for legionellosis (3-5 days for non-severe cases, 10-14 days for severe cases and/or immunocompromised patients), prospective studies remain needed.